JP2024541975A5 - - Google Patents

Info

Publication number
JP2024541975A5
JP2024541975A5 JP2024525308A JP2024525308A JP2024541975A5 JP 2024541975 A5 JP2024541975 A5 JP 2024541975A5 JP 2024525308 A JP2024525308 A JP 2024525308A JP 2024525308 A JP2024525308 A JP 2024525308A JP 2024541975 A5 JP2024541975 A5 JP 2024541975A5
Authority
JP
Japan
Prior art keywords
alkyl
disease
independently
halogen
structural part
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525308A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541975A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/079290 external-priority patent/WO2023081812A2/en
Publication of JP2024541975A publication Critical patent/JP2024541975A/ja
Publication of JP2024541975A5 publication Critical patent/JP2024541975A5/ja
Pending legal-status Critical Current

Links

JP2024525308A 2021-11-05 2022-11-04 Akt3モジュレーター Pending JP2024541975A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163276073P 2021-11-05 2021-11-05
US63/276,073 2021-11-05
PCT/US2022/079290 WO2023081812A2 (en) 2021-11-05 2022-11-04 Akt3 modulators

Publications (2)

Publication Number Publication Date
JP2024541975A JP2024541975A (ja) 2024-11-13
JP2024541975A5 true JP2024541975A5 (cg-RX-API-DMAC10.html) 2025-11-12

Family

ID=86242221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525308A Pending JP2024541975A (ja) 2021-11-05 2022-11-04 Akt3モジュレーター

Country Status (10)

Country Link
US (1) US20250074905A1 (cg-RX-API-DMAC10.html)
EP (1) EP4426706A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024541975A (cg-RX-API-DMAC10.html)
KR (1) KR20240116621A (cg-RX-API-DMAC10.html)
CN (1) CN118488956A (cg-RX-API-DMAC10.html)
AU (1) AU2022381198A1 (cg-RX-API-DMAC10.html)
CA (1) CA3236906A1 (cg-RX-API-DMAC10.html)
IL (1) IL312439A (cg-RX-API-DMAC10.html)
MX (1) MX2024005207A (cg-RX-API-DMAC10.html)
WO (1) WO2023081812A2 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021212111A1 (en) * 2020-04-17 2021-10-21 Augusta University Research Institute, Inc. Compositions and methods for treating leukemia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US7534423B2 (en) 2003-03-28 2009-05-19 Faron Pharmaceuticals Oy Method for inducing an elevated level of adenosine in an individual
WO2006135627A2 (en) * 2005-06-10 2006-12-21 Merck & Co., Inc. Inhibitors of akt activity
CA2678180A1 (en) 2007-02-13 2008-12-04 Northeastern University Methods and compositions for improving immune responses
US11291719B2 (en) * 2016-01-15 2022-04-05 Augusta University Research Institute, Inc. Methods and compositions for modulating Akt3
US20230295114A1 (en) * 2020-05-08 2023-09-21 Georgiamune Llc Akt3 modulators

Similar Documents

Publication Publication Date Title
ES2735087T3 (es) Compuestos de pirimidina fusionados para el tratamiento de VIH
JP2024540107A5 (cg-RX-API-DMAC10.html)
JP2024541995A5 (cg-RX-API-DMAC10.html)
TWI711621B (zh) 經取代之多環性吡啶酮衍生物及含有其前體之醫藥組合物
CN111263767B (zh) 作为干扰素基因调节剂的刺激剂的环状二核苷酸
AU2015371257B2 (en) Isoquinoline compounds for the treatment of HIV
JP2021517132A (ja) 4’−ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用
US8815918B2 (en) Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives
JP2019501133A5 (cg-RX-API-DMAC10.html)
JP2021513973A (ja) ピリジン誘導体およびhiv感染を処置するためのその使用
JP2016529324A5 (cg-RX-API-DMAC10.html)
JP2018527011A5 (cg-RX-API-DMAC10.html)
EA035746B1 (ru) Производные хиназолина, применяемые для лечения вич
JP2013535460A5 (cg-RX-API-DMAC10.html)
BR0316407A (pt) Derivados de nucleosìdeo antiviral
HRP20230452T1 (hr) Modulatori piruvat kinaze i njihova uporaba
JP2023525757A5 (cg-RX-API-DMAC10.html)
HRP20180916T1 (hr) Inhibitori demetilaze od lsd1 na bazi arilciklopropilamina i njihova medicinska uporaba
JP2023164918A5 (cg-RX-API-DMAC10.html)
JP2014512364A5 (cg-RX-API-DMAC10.html)
ES2659424T3 (es) Terapia de combinación para el cáncer
JP2014510147A5 (cg-RX-API-DMAC10.html)
JP2024541994A5 (cg-RX-API-DMAC10.html)
JP7129703B2 (ja) アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
JP2023524600A5 (cg-RX-API-DMAC10.html)